Your browser doesn't support javascript.
loading
Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam.
Nguyen, Thi-Phuong-Lan; Wright, E Pamela; Nguyen, Thanh-Trung; Schuiling-Veninga, C C M; Bijlsma, M J; Nguyen, Thi-Bach-Yen; Postma, M J.
Afiliação
  • Nguyen TP; University of Groningen, Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics, Groningen, the Netherlands.
  • Wright EP; Medical Committee Netherlands-Vietnam, Amsterdam, The Netherlands.
  • Nguyen TT; Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen, Vietnam.
  • Schuiling-Veninga CC; University of Groningen, Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics, Groningen, the Netherlands.
  • Bijlsma MJ; University of Groningen, Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics, Groningen, the Netherlands.
  • Nguyen TB; Department of Health economic, Ha Noi University of Medicine, Ha Noi, Vietnam.
  • Postma MJ; University of Groningen, Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics, Groningen, the Netherlands.
PLoS One ; 11(5): e0155699, 2016.
Article em En | MEDLINE | ID: mdl-27192051
ABSTRACT

OBJECTIVE:

To inform development of guidelines for hypertension management in Vietnam, we evaluated the cost-effectiveness of different strategies on screening for hypertension in preventing cardiovascular disease (CVD).

METHODS:

A decision tree was combined with a Markov model to measure incremental cost-effectiveness of different approaches to hypertension screening. Values used as input parameters for the model were taken from different sources. Various screening intervals (one-off, annually, biannually) and starting ages to screen (35, 45 or 55 years) and coverage of treatment were analysed. We ran both a ten-year and a lifetime horizon. Input parameters for the models were extracted from local and regional data. Probabilistic sensitivity analysis was used to evaluate parameter uncertainty. A threshold of three times GDP per capita was applied.

RESULTS:

Cost per quality adjusted life year (QALY) gained varied in different screening scenarios. In a ten-year horizon, the cost-effectiveness of screening for hypertension ranged from cost saving to Int$ 758,695 per QALY gained. For screening of men starting at 55 years, all screening scenarios gave a high probability of being cost-effective. For screening of females starting at 55 years, the probability of favourable cost-effectiveness was 90% with one-off screening. In a lifetime horizon, cost per QALY gained was lower than the threshold of Int$ 15,883 in all screening scenarios among males. Similar results were found in females when starting screening at 55 years. Starting screening in females at 45 years had a high probability of being cost-effective if screening biannually was combined with increasing coverage of treatment by 20% or even if sole biannual screening was considered.

CONCLUSION:

From a health economic perspective, integrating screening for hypertension into routine medical examination and related coverage by health insurance could be recommended. Screening for hypertension has a high probability of being cost-effective in preventing CVD. An adequate screening strategy can best be selected based on age, sex and screening interval.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Programas de Rastreamento / Análise Custo-Benefício / Hipertensão Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Health_economic_evaluation / Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Programas de Rastreamento / Análise Custo-Benefício / Hipertensão Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Health_economic_evaluation / Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda